Tumor-infiltrating lymphocyte (TIL) therapy

About this approach

TIL therapy collects immune cells that have entered a patient's tumor, expands selected cells in a laboratory, and returns them by infusion after preparative chemotherapy. It is an intensive, individualized treatment delivered by specialized cell-therapy programs rather than a simple infusion available at every oncology clinic.

Where it fits: Personalized cell therapy for selected advanced melanoma

Where this treatment is used

The FDA has approved lifileucel for selected adults with unresectable or metastatic melanoma previously treated with specified therapies. Research continues in other cancers, but those uses should be identified as clinical trials or investigational care. Tumor collection, manufacturing, conditioning chemotherapy, and supportive care are all part of the treatment pathway.

Procedure and practical considerations

Risks include severe low blood counts, infection, bleeding, organ complications, and effects from conditioning chemotherapy and interleukin-2 support. Treatment may require surgery to obtain tumor tissue, hospitalization, and recovery near an experienced center. Manufacturing can take time and may not produce a usable treatment for every patient.

Cancer guides that discuss this treatment

These cancer-type guides include this treatment among their connected approaches. Open a guide to see the related terminology, treatments, and clinic profiles.

Clinics reporting this approach

These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.